246 related articles for article (PubMed ID: 30980126)
1. Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy.
Gu KW; Kim CK; Choi CH; Yoon YC; Park W
Eur Radiol; 2019 Nov; 29(11):6236-6244. PubMed ID: 30980126
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of diffusion-weighted magnetic resonance imaging and
Park JJ; Kim CK; Park BK
Radiother Oncol; 2016 Sep; 120(3):507-511. PubMed ID: 26900089
[TBL] [Abstract][Full Text] [Related]
3. Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy.
Lin G; Yang LY; Lin YC; Huang YT; Liu FY; Wang CC; Lu HY; Chiang HJ; Chen YR; Wu RC; Ng KK; Hong JH; Yen TC; Lai CH
Eur Radiol; 2019 Feb; 29(2):556-565. PubMed ID: 30051142
[TBL] [Abstract][Full Text] [Related]
4. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.
Ho JC; Allen PK; Bhosale PR; Rauch GM; Fuller CD; Mohamed AS; Frumovitz M; Jhingran A; Klopp AH
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):546-553. PubMed ID: 28011045
[TBL] [Abstract][Full Text] [Related]
5. Value of blood oxygenation level-dependent MRI for predicting clinical outcomes in uterine cervical cancer treated with concurrent chemoradiotherapy.
Lee J; Kim CK; Gu KW; Park W
Eur Radiol; 2019 Nov; 29(11):6256-6265. PubMed ID: 31016443
[TBL] [Abstract][Full Text] [Related]
6. Can diffusion-weighted magnetic resonance imaging predict tumor recurrence of uterine cervical cancer after concurrent chemoradiotherapy?
Bae JM; Kim CK; Park JJ; Park BK
Abdom Radiol (NY); 2016 Aug; 41(8):1604-10. PubMed ID: 27056747
[TBL] [Abstract][Full Text] [Related]
7. Treatment response evaluation using the mean apparent diffusion coefficient in cervical cancer patients treated with definitive chemoradiotherapy.
Onal C; Erbay G; Guler OC
J Magn Reson Imaging; 2016 Oct; 44(4):1010-9. PubMed ID: 26919800
[TBL] [Abstract][Full Text] [Related]
8. Prediction of disease progression following concurrent chemoradiotherapy for uterine cervical cancer: value of post-treatment diffusion-weighted imaging.
Park JJ; Kim CK; Park BK
Eur Radiol; 2016 Sep; 26(9):3272-9. PubMed ID: 26685853
[TBL] [Abstract][Full Text] [Related]
9. Predicting tumor recurrence in patients with cervical carcinoma treated with definitive chemoradiotherapy: value of quantitative histogram analysis on diffusion-weighted MR images.
Erbay G; Onal C; Karadeli E; Guler OC; Arica S; Koc Z
Acta Radiol; 2017 Apr; 58(4):481-488. PubMed ID: 27445314
[TBL] [Abstract][Full Text] [Related]
10. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.
Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M
BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349
[TBL] [Abstract][Full Text] [Related]
11. Potentialities of multi-b-values diffusion-weighted imaging for predicting efficacy of concurrent chemoradiotherapy in cervical cancer patients.
Liu B; Ma WL; Zhang GW; Sun Z; Wei MQ; Hou WH; Hou BX; Wei LC; Huan Y
BMC Med Imaging; 2020 Aug; 20(1):97. PubMed ID: 32799809
[TBL] [Abstract][Full Text] [Related]
12. Early alteration in apparent diffusion coefficient and tumor volume in cervical cancer treated with chemoradiotherapy or radiotherapy: Incremental prognostic value over pretreatment assessments.
Watanabe Y; Nakamura S; Ichikawa Y; Ii N; Kawamura T; Kondo E; Ikeda T; Nomoto Y; Sakuma H
Radiother Oncol; 2021 Feb; 155():3-9. PubMed ID: 33039422
[TBL] [Abstract][Full Text] [Related]
13. Volumetric assessment of apparent diffusion coefficient predicts outcome following chemoradiation for cervical cancer.
Ho JC; Fang P; Cardenas CE; Mohamed ASR; Fuller CD; Allen PK; Bhosale PR; Frumovitz MM; Jhingran A; Klopp AH
Radiother Oncol; 2019 Jun; 135():58-64. PubMed ID: 31015171
[TBL] [Abstract][Full Text] [Related]
14. The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy.
Wang L; Liu L; Han C; Liu S; Tian H; Li Z; Ren X; Shi G; Wang Q; Wang G
Radiother Oncol; 2016 Nov; 121(2):246-251. PubMed ID: 27838148
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for uterine cervical cancer.
Makino H; Kato H; Furui T; Morishige K; Kanematsu M
J Obstet Gynaecol Res; 2014 Apr; 40(4):1098-104. PubMed ID: 24320754
[TBL] [Abstract][Full Text] [Related]
16. Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer.
Ueno Y; Lisbona R; Tamada T; Alaref A; Sugimura K; Reinhold C
Br J Radiol; 2017 Jul; 90(1075):20170035. PubMed ID: 28508679
[TBL] [Abstract][Full Text] [Related]
17. Assessment of early response to concurrent chemoradiotherapy in cervical cancer: value of diffusion-weighted and dynamic contrast-enhanced MR imaging.
Park JJ; Kim CK; Park SY; Simonetti AW; Kim E; Park BK; Huh SJ
Magn Reson Imaging; 2014 Oct; 32(8):993-1000. PubMed ID: 24970025
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment diffusion-weighted MR imaging for predicting tumor recurrence in uterine cervical cancer treated with concurrent chemoradiation: value of histogram analysis of apparent diffusion coefficients.
Heo SH; Shin SS; Kim JW; Lim HS; Jeong YY; Kang WD; Kim SM; Kang HK
Korean J Radiol; 2013; 14(4):616-25. PubMed ID: 23901319
[TBL] [Abstract][Full Text] [Related]
19. Added-value of texture analysis of ADC in predicting the survival of patients with 2018 FIGO stage IIICr cervical cancer treated by concurrent chemoradiotherapy.
Zhang X; Zhang Q; Guo J; Zhao J; Xie L; Zhang J; An J; Yu X; Zhao X
Eur J Radiol; 2022 May; 150():110272. PubMed ID: 35334244
[TBL] [Abstract][Full Text] [Related]
20. Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy.
Kim KA; Park MS; Ji HJ; Park JY; Han KH; Kim MJ; Kim KW
J Magn Reson Imaging; 2014 Feb; 39(2):286-92. PubMed ID: 24302545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
